Document is current
Any future updates will be listed below
-
Authors
Harris, Ethan J.
Karaoglu, Diren Arda
Sukhanova, Madina
Abaza, Yasmin https://orcid.org/0000-0002-9156-7912
Karantanos, Theodoros
Eisfeld, Ann-Kathrin
Anderson, Clare
Lin, Chenyu https://orcid.org/0000-0002-4542-4232
Moreno Vanegas, Yenny A.
Badar, Talha https://orcid.org/0000-0003-1548-918X
Coltoff, Alexander
Knepper, Todd C.
Ozkaya, Neval
Youshanlouei, Hamed Rahmani
Cetin, Sinan https://orcid.org/0009-0001-3572-7600
Patel, Anand A. https://orcid.org/0000-0002-0296-8686
DuVall, Adam S. https://orcid.org/0000-0002-9163-8792
Drazer, Michael W.
Wang, Peng
Tjota, Melissa
Segal, Jeremy P.
Venkataraman, Girish https://orcid.org/0000-0002-8674-2608
Gurbuxani, Sandeep https://orcid.org/0000-0003-0716-8730
Cheng, Jason X.
Arber, Daniel A. https://orcid.org/0000-0002-2160-9689
Larson, Richard A. https://orcid.org/0000-0001-9168-3203
Odenike, Olatoyosi
Webster, Jonathan
Shah, Bijal
Stock, Wendy https://orcid.org/0000-0002-8349-9200
Saygin, Caner https://orcid.org/0000-0001-7617-8356
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (HT94252510221)
American Society of Hematology
- License Information
-
More Information
Article History
Received: 8 June 2025
Revised: 15 July 2025
Accepted: 5 August 2025
First Online: 14 August 2025
Competing interests
: A-KE’s spouse is employed by Karyopharm Therapeutics, she serves on the scientific advisory boards of Syndax, Daiichi Sankyo, and Servier, as well as the DEI AB of Astra Zeneca. CL is on the Advisory Board of Autolus, ADC therapeutics, and consults for Rigel. AC received honoraria from Sobi, PharmaEssentia, and research funding from Merck, Kartos, Oncoverity. AAP received honoraria from AbbVie, Amgen, Astellas, Jazz, Sobi, Syndax; research funding from Pfizer, Servier, Incyte, Sumitomo. MWD has consulting or advisory roles (Argenx, Blueprint Medicines); honoraria for educational writing (American Society of Hematology Self-Assessment Program); honoraria (Novartis). RAL has acted as a consultant or advisor to Ariad/Takeda, CVS/Caremark, Daiichi Sankyo, Epizyme/Ipsen, and Novartis, and has received clinical research support to his institution from Ascentage, Astellas, Biomea Fusion, Cellectis, Daiichi Sankyo, and Novartis, and royalties from UpToDate.
: The study was approved by the institutional review boards and ethical committee clearance was obtained (IRB09-130-B and IRB16-0892). All clinical investigations were conducted according to the principles of the Declaration of Helsinki. Informed consent was obtained from all study participants or their legal guardians.
